Supporting Information

Multi-responsive graft copolymer micelles comprising acetal and disulfide linkages for stimuli-triggered drug delivery

Huanhuan Liu, Cangxia Li, Dandan Tang, Xiaonan An, Yanfei Guo and Youliang Zhao*

Suzhou Key Laboratory of Macromolecular Design and Precision Synthesis, Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China

Aggregates	T (°C)	pН	DTT	<i>K</i> (h ⁻¹)	CR (%)	ICR (%)
G3	25	7.4	none	0.063	36.1	0
G3	25	5.3	yes	0.174	59.9	65.9
G3	37	7.4	none	0.158	48.3	33.8
G3	37	7.4	yes	0.238	67.4	86.7
G3	37	5.3	none	0.278	63.0	74.5
G3	37	5.3	yes	0.403	77.1	114
G3/β-CD	25	7.4	none	0.139	45.4	0
G3/β-CD	25	5.3	yes	0.178	61.8	36.1
G3/β-CD	37	7.4	none	0.236	52.4	15.4
G3/β-CD	37	7.4	yes	0.325	64.4	41.9
G3/β-CD	37	5.3	none	0.293	67.2	48.0
G3/β-CD	37	5.3	yes	0.458	78.6	73.1

Table S1. Dependence of apparent drug-release rate (*K*), cumulative release (CR) and increment of cumulative release (ICR) at 48 h on external stimuli during in vitro DOX releases from G3 aggregates or $G3/\beta$ -CD coaggregates



Fig. S1 1 H (top) and 13 C (bottom) NMR spectra of VCP.



Fig. S2 IR spectrum of 4-(vinyloxy)butyl 4-cyano-4-(phenylcarbonothioylthio)pentanoate (VCP).



Fig. S3 ¹H NMR spectrum of vinyloxy-terminated PNIPAM.



Fig. S4 IR spectra of PNIPAM (a), poly(HEMA-*co*-PEGMEMA) (G1, b), poly(PEG-*co*-PCL) (G2, c), and poly(PEG-*co*-PCL)-*graft*-PNIPAM (G3, d).



Fig. S5 DSC traces of various polymers.



Fig. S6 TEM image of G3/ β -CD coaggregates ($c_{polymer} = 0.50 \text{ mg mL}^{-1}$, $c_{\beta-CD} = 1.0 \text{ mM}$) formed at 37 °C.



Fig. S7 Cell viability of 4T1 cells incubated with β -CD aqueous solution at various concentrations at 37 °C for 24 h. Error bars denote standard deviations from three parallel trials.



Fig. S8 Cell viability of 4T1 cells incubated with G3 aggregates at various concentrations at 37 °C for 24 h. Error bars denote standard deviations from three parallel trials.